Evening Primrose Oil Improves Chemotherapeutic Effects in Human Pancreatic Ductal Adenocarcinoma Cell Lines-A Preclinical Study

Evening Primrose oil (EPO), obtained from the seeds of Evening Primrose ( L.), is largely used as a dietary supplement, especially after cancer diagnosis. Human pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease correlated with poor clinical prognosis and a very low response rate to co...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceuticals (Basel, Switzerland) Switzerland), 2022-04, Vol.15 (4), p.466
Main Authors: Zeppa, Laura, Aguzzi, Cristina, Versari, Giorgia, Luongo, Margherita, Morelli, Maria Beatrice, Maggi, Federica, Amantini, Consuelo, Santoni, Giorgio, Marinelli, Oliviero, Nabissi, Massimo
Format: Article
Language:English
Subjects:
Apoptosis
Cancer therapies
chemoresistance
Chemotherapy
Cytotoxicity
Drug dosages
evening primrose oil
human pancreatic ductal adenocarcinoma
Mortality
Oenothera biennis
paclitaxel chemoresistance
Pancreatic cancer
PMS
Premenstrual syndrome
Protein expression
Proteins
Seeds
Sterols
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Evening Primrose oil (EPO), obtained from the seeds of Evening Primrose ( L.), is largely used as a dietary supplement, especially after cancer diagnosis. Human pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease correlated with poor clinical prognosis and a very low response rate to common chemotherapy. The aim of this work was to study the potential ability of EPO to improve the effects of chemotherapeutic drugs in PANC-1 and MIAPaCa-2 cell lines. Cytotoxicity, cell death, reactive oxygen species (ROS) production and EPO anticancer activity associated with the main chemotherapeutic drugs commonly used in therapy were investigated. Results showed that EPO reduced PDAC cell viability and increased paclitaxel efficacy. This evidence suggests that EPO may be used as a potential supplement to increase chemotherapeutic efficacy in PDAC therapy.
ISSN:1424-8247
1424-8247
DOI:10.3390/ph15040466